RESEARCH PAPER

Taylor & Francis

OPEN ACCESS Check for updates

Flavonoids as tyrosinase inhibitors in *in silico* and *in vitro* models: basic framework of SAR using a statistical modelling approach

Katarzyna Jakimiuk^a (), Suat Sari^b (), Robert Milewski^c (), Claudiu T. Supuran^d (), Didem Şöhretoğlu^e () and Michał Tomczyk^a

^aDepartment of Pharmacognosy, Faculty of Pharmacy with the Division of Laboratory Medicine, Medical University of Białystok, Białystok, Poland; ^bDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey; ^cDepartment of Statistics and Medical Informatics, Faculty of Health Science, Medical University of Białystok, Białystok, Poland; ^dNeurofarba Department, Universita degli Studi di Firenze, Florence, Italy; ^eDepartment of Pharmacognosy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey

ABSTRACT

Flavonoids are widely distributed in plants and constitute the most common polyphenolic phytoconstituents in the human diet. In this study, the *in vitro* inhibitory activity of 44 different flavonoids (**1–44**) against mushroom tyrosinase was studied, and an *in silico* study and type of inhibition for the most active compounds were evaluated too. Tyrosinase inhibitors block melanogenesis and take part in melanin production or distribution leading to pigmentation diseases. The *in vitro* study showed that quercetin was a competitive inhibitor (IC₅₀=44.38±0.13 μ M) and achieved higher antityrosinase activity than the control inhibitor kojic acid. The *in silico* results highlight the importance of the flavonoid core with a hydroxyl at C7 as a strong contributor of interference with tyrosinase activity. According to the developed statistical model, the activity of molecules depends on hydroxylation at C3 and methylation at C8, C7, and C3 in the benzo- γ -pyrane ring of the flavonoids. **ARTICLE HISTORY**

Received 4 November 2021 Accepted 30 November 2021

KEYWORDS

Flavonoid; molecular docking; tyrosinase; structure-activity relationship; statistical analysis

1. Introduction

Flavonoids are secondary plant metabolites that can be chemically divided into groups based on their substitutions. Flavonoid moieties can be modified by glycosylation, hydrogenation, hydroxylation, acetylation and methylation, as well as by malonylation and sulfatation. The chemical and biological potentials of flavonoids and their derivatives are connected with the position of diverse substitutions on the molecule and the saturation of double bonds in the structure¹. Thus, structure-activity relationship (SAR) studies can help predict the biological activities of compounds with related structures and help avoid off-target outcomes due to their toxicity and side effects. The substantial contribution of a treatment is based on selecting the right medicine for a given target. Available theoretical tools (e.g., molecular docking studies) can help predict potential inhibitory activity against enzymes, including tyrosinase, and virtual screening can be used to select compounds that target tyrosinase and to determine expected targets for well-known and newly discovered flavonoids^{2,3}. Tyrosinase is common in mammals, fungi, bacteria, and plants, and it plays a critical role in melanin biosynthesis. Tyrosinase consists of two identical H subunits as a catalytic component and two identical L subunits. The H subunit includes four helices that contain the catalytic binuclear copper-binding site. Each Cu²⁺ cofactor forms coordination bonds with three histidine residues (His61, His85, His94, and His259, His263, His296, respectively) located at the centre of two antiparallel α helix pairs^{4,5}. His85 is covalently bound to Cys83 through a thioether bond, and these two residues are connected to each other via a threonine residue that forms a

triad motif that is conserved among tyrosinases and is considered essential for catalytic activity^{6,7}. The histidine ligands of the copper ions are stabilised via interactions with nearby residues such as Phe90 and Phe292 for catalytic activity; thus, interactions with the copper ions as well as their ligands and the nearby residues are required for effective inhibition^{8,9}. In humans, abnormal melanin production or distribution leads to pigmentation diseases, such as overtanning, freckles, age spots, and melasma. Disorderly melanin production plays a key role in melanotic melanoma, and inhibiting tyrosinase activity may reduce melanin content and be a useful process in skin-whitening compounds^{10,11}.

In this study, we investigated the tyrosinase inhibitory activity of 44 flavonoids, (7-methoxynaringenin (1), 7,4'-dimethoxynaringenin (2), butin (3), isookanin (4), hesperetin (5), hesperetin 7-O-rutinoside (hesperidin) (6), 5-hydroxyflavone (7), 5-hydroxy-2'methoxyflavone (8), 5-hydroxy-2',6'-dimethoxyflavone (9), zapotin (10), chrysin (11), apigenin (12), apigenin 7-O-glucoside (cosmosiin) (13), apigenin 8-C-glucoside (vitexin) (14), apigenin 8-C-glucosyl-2"-O-glucoside (15), acacetin (16), luteolin (17), luteolin 7-Oglucoside (cynaroside) (18), luteolin 7-O-sambubioside (19), luteolin-6-C-glucoside (isoorientin) (20), chrysoeriol (21), 5,7,3'-trihydroxy-4'-methoxyflavone-8-C-xylopyranoside-2"-O-glucoside (scleranthoside A) (22), 5,7,3'-trihydroxy-4'-acetoxyflavone-8-Cxylopyranoside-2"-O-glucoside (scleranthoside B) (23), 5,7-dihydroxy-3'-methoxy-4'-acetoxyflavone-8-C-xylopyranoside-2"-O-glucoside 5,7-dihydroxy-3'-methoxy-4'-acetoxyflavone-8-C-(24), xylopyranoside-2"-O-(4'"-acetoxy)-glucoside (scleranthoside D) (25), kaempferol (26), 8-methoxykaempferol (27), kumatakenin (28),

CONTACT Michał Tomczyk i michal.tomczyk@umb.edu.pl Department of Pharmacognosy, Faculty of Pharmacy with the Division of Laboratory Medicine, Medical University of Białystok, Białystok, Poland

 $\ensuremath{\mathbb{C}}$ 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

kaempferol 3-O-glucoside (astragalin) (29), kaempferol 3-O-glucuronide (30), kaempferol 3-O-galactoside (hyperoside) (31), kaemp-3-O-(6"-O-trans-p-coumaroyl)-glucoside (tiliroside) ferol (32), ermanin (33), icariin (34), guercetin (35), guercetin 3-O-glucuronide (miquelianin) (36), quercetin 3-O-rutinoside (rutin) (37), quercetin 3-O-rutinoside-7-O-glucoside (38), 7-O-methoxyquercetin (rhamnetin) (39), 7-O-methoxyquercetin (isorhamnetin) (40), robinetin (41), myricetin (42), daidzein (43), and genistein (44), to find potentially active compounds. First, tyrosinase inhibition and enzyme kinetics were tested in an in vitro model to determine the types of inhibition for the compounds with the highest activity. Second, in an *in silico* model, docking studies were performed to describe SARs, which were also assessed using a statistical model. Thus, a combination of bioinformatics simulation and biological in vitro studies describe the functional mechanisms of the tested compounds.

2. Materials and methods

2.1. Chemical and reagents

Kojic acid (CAS number: 501-30-4), 3,4-dihydroxy-L-phenylalanine (L-DOPA) (CAS number: 59-92-7; purity \geq 98%), and tyrosinase from mushrooms (CAS number: 9002-10-2) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). Compounds 5 (CAS number: 69097-99-0), 11 (CAS number: 480-40-0), 12 (CAS number: 520-36-5), 14 (CAS number: 3681-93-4), 20 (CAS number: 4261-42-1), 21 (CAS number: 491-71-4), 26 (CAS number: 520-18-3), 35 (CAS number: 6151-25-3), 39 (CAS number: 90-19-7), 40 (CAS number: 480-19-3), 42 (CAS number: 529-44-2) and 44 (CAS number: 446-72-0) were obtained from Carl Roth (Karlsruhe, Germany), 16 (CAS number: 480-44-4), 34 (CAS number: 489-32-7), and 43 (CAS number: 552-66-9) were obtained from Cayman Chemical (Ann Arbour, MI, USA). Flavonoids 1, 2, 28, 33¹², 13¹³, 15, 31, 38¹⁴, 17¹⁵, 18, 19¹⁶, 7, 8, 9¹⁷, 22, 23, 24, 25¹⁸, 27, 32¹⁹, 29, and 37²⁰ were isolated and identified in the Department of Pharmacognosy at the Medical University of Białystok. Compounds 3 (CAS number: 492-14-8), 4 (CAS number: 1036-49-3), and 10 (CAS number: 14813-19-5) were purchased from Biosynth Carbosynth (London, UK), 6 (CAS number: 520-26-3) and 41 (CAS number: 490-31-3) were purchased from Fluka Analysis (St. Louis, MO, USA), and 30 (CAS number: 22688-78-4) and 36 (CAS number: 22688-79-5) were obtained from Extrasynthese (Genay, France). All isolated compounds were >95% pure as measured by HPLC. Bioassay was performed on BioTek Instruments microplate spectrophotometer EPOCH 2 (Oxfordshire, UK).

2.2. Tyrosinase inhibition assay

The inhibitory effect on mushroom tyrosinase (TYase) was evaluated using a method reported in the literature with some modifications²¹. This assay was performed in PBS (100 mM, pH = 6.8 in 25 °C). Test samples **1–44** (80 µL) were preincubated with TYase solution (40 µL; 250 U/mL) at 25 °C for 10 min. Then, L-DOPA (80 µL; 0.19 mg/mL) was added, and after an additional 10 min at 25 °C, the absorbance was measured at 492 nm. A blank analysis was performed using PBS instead of a sample, and the positive control was conducted with kojic acid. The inhibitory effect was calculated as follows:

TYaseInh (%) = $\left[(B - C)/C \right] \times 100$

where B and C are the absorbances of the blank and the compounds, respectively. The compound concentration that inhibits 50% of tyrosinase activity (IC_{50}) was calculated. All tests were performed in triplicate.

2.3. Tyrosinase inhibition kinetic analysis

Based on IC_{50} values, the seven most active compounds (4, 17, 26, 32, 35, 41) were selected for kinetic analysis. The enzyme reaction kinetics of these compounds were measured by constructing Lineweaver-Burk plots of inverse velocities (1/*V*), contrary to the inverse of substrate concentration $(1/5)^{22,23}$. Preincubations and measurement times were performed using the same protocol as described above. The enzyme concentration (250 U/mL) was kept constant in the presence of substrate solutions (L-DOPA) between 0.25 and 2 mM in all kinetic studies. The inhibitor concentrations for all test compounds were 0, 25, and 50 μ M. The inhibitory types and inhibitory constant (*K_i*) values were described by 1/*V* versus inhibitor concentration plots (Dixon plot).

2.4. Molecular docking

The selected flavonoids were sketched in ACD/ChemSketch to build and generate their mol topology format. The compounds were modelled using LigPrep (2021-22, Schrödinger LLC, New York, NY) and MacroModel (2021–22, Schrödinger LLC, New York, NY) according to the OPLS4 forcefield parameters²⁴ and conjugate gradients method. The original configurations of the ligands were conserved, and their ionisation states at pH 7 were modelled. The mushroom tyrosinase structure (PDB ID: 2Y9X⁵; resolution: 2.78 Å) was downloaded from the RCSB protein data bank (www.rcsb. org)²⁵ and prepared for docking using the Protein Preparation Wizard of Maestro (2021–22, Schrödinger LLC, New York, NY)²⁶. In this process, redundant molecules were removed, H atoms were added, partial charges were assigned, and ionisation, tautomeric states, and H bonds were set. The active site grids were generated using the Receptor Grid Generator panel of Maestro by setting the central coordinates as -0.62, 26.99, and -43.78, and the volume as 27.000 $Å^3$. The ligand was docked to the active site using Glide (2021-2, Schrödinger LLC, New York, NY) in additional precision (XP) mode with 50 runs per ligand, and the results were visually evaluated²⁷. Prior to docking of the ligands, the co-crystallized ligand in the PDB structure, tropolone, was removed and redocked to the active site, and the obtained binding mode was compared with the co-crystallized conformer by calculating the root-mean-square deviation (RMSD) to confirm the precision of the method. The predicted binding mode for tropolone was similar to that of the original conformer (RMSD: 1.33 Å).

2.5. Statistical analysis

Statistical analysis for IC₅₀ calculations was performed using nonlinear regression using GraphPad Prism 9 (Trail, GraphPad Software, La Jolla, CA, USA). Data were collected as mean \pm SD (n = 3), and the significance of differences was analysed using one-way analysis of variance (ANOVA). Statistical analysis of SARs was performed using Stata/IC 13.1 (StataCorp LP, TX 77845, USA).

3. Results and discussion

3.1. Inhibitory effects of tested compounds on tyrosinase

The effects of different concentrations of selected flavonoids (Figure 1) and kojic acid, a well-known inhibitor of L-DOPA



Figure 1. Molecular structures of the tested compounds.

oxidation by tyrosinase, were studied. The effects, expressed as IC_{50} values, are shown in Table 1.

Although the rendered activity is accumulative of an entire molecule, a structure-activity relationship was recognised by examining the effect of different substitutions: the presence or absence of hydroxyl groups or their methylation/acetylation/glyco-sylation in all carbons of the B-ring, as well as in carbons 3, 5, 6, 7, and 8 of the benzo- γ -pyrane ring, on the potential inhibitory activity.

Some flavonoids (**4**, **17**, **35**) exhibited IC₅₀ values that were comparable to the positive control, kojic acid (IC₅₀=49.48 ± 0.23 μ M). Compound **4** (IC₅₀=58.43 ± 0.38 μ M), tested in this study for the first time, was one of the most effective inhibitors of tyrosinase, along with compound **17** (IC₅₀=58.88 ± 0.78 μ M) and compound **35** (IC₅₀=44.38 ± 0.13 μ M). The distinction in position C3 in **35** and **36** (IC₅₀=220.10 ± 1.14 μ M) or **37** (IC₅₀=141.67 ± 1.30 μ M) is only a difference in the glycosylation of a hydroxyl group. However, this small difference in their structure causes immense differences in their inhibitory potentials. It is presumed that substitutions at C3 led to steric hindrances that prevent molecules from binding to enzymes. However, the most typical locations for C-glycosyl radicals are the C6 and C8 positions at the A-ring. It seems that aglycone **4** (IC₅₀=58.43 ± 0.38 μ M) is a more effective tyrosinase inhibitor than it glycoside: **20** (IC₅₀=132.55 ± 2.32 μ M). The

exact location of the glycosidic residue (carbon 6 or 8) does not affect activity. Also, disaccharides linked with the flavonoid core in C8 (22, 23, 24, 25) exhibit weak inhibitory potential with IC₅₀ values that are higher than those of the maximum tested concentration. When the antityrosinase activity of methylated 26, 27, and **28** molecules with IC₅₀ values $65.11 \pm 1.09 \mu$ M, 290.46 ± 1.19 μ M, and $>500 \ \mu$ M, respectively, was compared, the presence of methyl groups likely prevents appropriate interactions with the enzyme active site²⁸. The same SAR pattern was observed with compounds 4 (without methylation), 1 (one methyl group at C7), and 2 (two methyl groups at C7, C4'), with IC_{50} values of 58.43 \pm 0.38 $\mu\text{M},\,441.92\pm1.91$ $\mu\text{M},\,\text{and}\,>500$ $\mu\text{M},\,\text{respectively}.$ The links of the B-ring in the C-ring allow flavone and isoflavone activity to be compared. Isoflavones (3-B-ring) with IC₅₀ values >500 μ M (**43** and **44**) exhibit no inhibitory potential. Additionally, the confrontation of the activity of **35** (IC_{50} =44.38±0.13 μ M) with 42 (IC₅₀=100.33 \pm 1.86 μ M) leads to the conclusion that the additional hydroxyl group in C5' reduces phenol inhibitory potency. It was not possible to determine the IC₅₀ values of flavonoids 2, 21, 22, 23, 25, 28, 40, 43 and 44 up to 500 µM, which was the highest tested concentration. Thus, based on the in vitro study, molecules containing more unsubstituted hydroxyl groups in C3, C5, and C7, as well as in C3' and C4', generally achieve highly potent activity against tyrosinase, this finding is consistent with previous

Table 1. Compounds 1–44 measured for anti-tyrosinase activity and their respective IC₅₀ values.

			B-ring					Benzo-y-pyrane ring					
No	π C2-C3	C2′ (R)	C3' (R ₁)	C4′ (R ₂)	C5′ (R 3)	C6′ (R ₄)	C3 (R ₅)	C5 (R ₆)	C6 (R ₇)	C7 (R ₈)	C8 (R ₉)	IC ₅₀ (μΜ)	
1	_	Н	Н	OH	Н	Н	H	OH	Н	OMe	Н	441.92 ± 1.91	
2	_	Н	Н	OMe	н	н	Н	OH	Н	OMe	н	>500	
3	_	Н	OH	OH	н	н	Н	Н	Н	OH	н	296.64 ± 2.81	
4	_	Н	OH	OH	Н	Н	Н	Н	Н	OH	OH	58.43 ± 0.38	
5	_	Н	OH	OMe	Н	Н	Н	OH	Н	OH	Н	237.49 ± 2.63	
6	_	Н	OH	OMe	Н	Н	Н	OH	Н	<i>O</i> -rut	Н	130.71 ± 1.40	
7	+	Н	Н	Н	Н	Н	Н	OH	Н	Н	Н	120.45 ± 1.48	
8	+	OMe	Н	Н	Н	Н	Н	OH	Н	Н	Н	122.06 ± 1.19	
9	+	OMe	Н	Н	Н	OMe	Н	OH	Н	Н	Н	127.00 ± 1.40	
10	+	OMe	н	н	н	OMe	Н	OMe	н	OMe	н	137.16 ± 1.44	
11	+	Н	н	н	н	Н	Н	OH	н	OH	н	129.42 ± 1.13	
12	+	н	н	OH	н	н	Н	OH	н	OH	н	160.52 ± 1.44	
13	+	н	н	OH	н	н	Н	OH	н	0-alc	н	3232 ± 1.11	
14	+	н	н	OH	н	н	Н	OH	н	OH	alc	133.07 ± 1.13	
15	+	н	н	OH	н	н	н	OH	н	ОН	alc-O-alc	159.07 ± 1.03 159.26 + 1.17	
16	+	н	н	OMe	н	н	H	ОН	н	ОН	gie o gie	207.86 ± 1.17	
17	+	н	OH	OH	н	н	H	ОН	н	ОН	н	207.00 ± 1.00 58.88 ± 0.78	
18	+	н	ОН	ОН	н	н	H	ОН	н	0-alc	н	415.00 ± 0.70	
10	+	н	ОН	ОН	н	н	H	ОН	н	0-xvl-alc	н	15926 ± 2.30	
20	+	н	ОН	ОН	н	н	H	ОН	alc	OH	н	132.20 ± 1.17 132.55 ± 2.32	
20	-	н		ОН	н	н	н	ОН	яс	ОН	н	_500	
21	-	н	OH		н	н	н	ОН	н	ОН	xyl-O-alc	>500	
22	-	Ц		01/c	Ц	ц	и Ц		Ц		xyl-O-glc	>500	
23	-	Ц	010	040	Ц	ц	и Ц		Ц		xyl-O-glc	>500	
27	-	Ц	OMo	040	Ц	ц	и Ц		Ц		(4 ^{///} acetoxy-xyl)-O-alc	>500	
25		Ц	Ц		и Ц	и Ц			Ц			2000 65 11 + 1 00	
20		Ц	и Ц		и Ц	и Ц			Ц		OMe	200.16 ± 1.09	
2/	- -	и Ц	и Ц		и Ц		OMo		и Ц	OMo		290.40 ± 1.19	
20	+	п Ц	п Ц		L L	п Ц	Orde		п		п Ц	>J00 401 54 ± 1 72	
29	+	п Ц	п Ц		L L	п ц	0-gic		п		п Ц	401.04 ± 1.70	
21	+	п Ц	п Ц		L L	п ц	O gal		п		п Ц	209.97 ± 1.23 196.01 ± 1.00	
27	+	п Ц	п Ц		L L	п ц	0 (6 ¹ / n Co) alc		п		п Ц	100.91 ± 1.09	
22 22	+	п Ц	п Ц		L L	п ц	$O^{-}(O^{-}p^{-}CO)^{-}gic$		п		п Ц	70.35 ± 0.04	
27	+	п Ц		OMe	L L	п ц	6 doovu al mon		п		П 2 Мо 2 Ри	231.72 ± 1.17 150.01 ± 1.04	
34	+	п							п	O-gic	5-Me-2-Bu	130.01 ± 1.04	
32	+	п							п		п ц	44.50 ± 0.15	
30 27	+						O-gluc				п ц	220.10 ± 1.14	
3/	+		OH		н	н 11	O-rut			O ele	н	141.07 ± 1.30	
38	+		OH		н	н 11	0-rut			0-gic	н	147.05 ± 1.57	
39	+	п		OH	п	п	OH	OH	п	Ome	н	1/0./1±2.05	
40	+	н	ONIE	OH	н	н	UH	UH	н	OH	Н	>500	
41	+	н	UH	UH	OH	H	UH	Н	н	UH	H	63.14 ± 0.85	
42	+	н	UH	UH	UH	H	UH	UH	н	UH	H	100.33 ± 1.86	
43	+	н	н	OH	н	н	Н	Н	н	OH	H	>500	
44	+	Н	Н	UH	Н	Н	Н	UH	Н	UH	Н	>500	

Abbreviations: π C2-C3 +/- present or absence of double bond; Me: methyl; Bu: butenyl; Ac: acetyl; glc: glucose; gluc: glucuronide; *p*-Co: *para*-coumaroyl; man: mannose; rut: rutinose; xyl: xylose.

study¹¹. Similar conclusions of SAR were presented using inhibitors of xanthine oxidase and elastase and scavengers of superoxide radicals^{29,30}.

3.2. Kinetic analysis of tyrosinase inhibition

Kinetic analysis of compound-induced inhibition was performed to determine the type of inhibition of the most active constituents (i.e., IC_{50} values below 100 μ M). Lineweaver-Burk plots (Figure 2) in double-reciprocal form and Dixon plots (Figure 3) were used to determine the inhibition types and evaluate the dissociation constants for the inhibitors (K_i) (Table 2). The inhibitory type of isookanin (4) and robinetin (41) was tested for the first time in this study.

As shown in Figure 2(A,B,F), the straight lines intersected at the same point on the x-axis, implying that the K_m value remained constant, while the maximum reaction rate (V_{max}) decreased with increasing concentrations of tested inhibitors (0, 25, and 50 μ M).

Thus, isookanin (4), luteolin (17) and robinetin (41) likely caused non-competitive tyrosinase inhibition. Compounds 4, 17 and 41 produce allosteric regulation, which is a specific type of enzyme inhibition that is characterised by an inhibitor binding to an allosteric site, resulting in decreased enzyme efficacy. The luteolin type of inhibition was consistent with previous studies³¹. The inhibition constant K_i was obtained from Dixon plots (Figure 3(A,B,F)) as $18.64\pm0.53 \mu$ M, $11.32\pm0.77 \mu$ M and $27.42\pm0.62 \mu$ M for compounds 4, 17, and 41, respectively.

In contrast, kaempferol (26), tiliroside (32) and quercetin (35) exhibit tyrosinase inhibition that are similar^{11,32,33}. As shown in Figure 2(C,D,E), all straight lines crossed at the same point on the y-axis, which indicated that V_{max} remained constant. As the x-axis intercepted increased with increasing inhibitor concentrations, K_m increased because a higher concentration of substrate is required to overcome the inhibitory effects of a competitor. Thus, compounds 26, 32, 35 can bind to the active site and prevent binding to the real substrate. Based on Dixon plots (Figure 3(C–E)), K_i for



Figure 2. Lineweaver–Burk plots for inhibition of tyrosinase in the presence of compounds: 4 (A), 17 (B), 26 (C), 32 (D), 35 (E), and 41 (F). The concentrations of the compounds were 0.00, 25, and 50 μ M. The substrate L-DOPA concentrations were 0.25, 0.50, 1, and 2 mM.

compounds **26**, **32**, **35** were calculated to be $40.20\pm0.46 \mu$ M, $9.83\pm0.57 \mu$ M, and $8.21\pm0.86 \mu$ M, respectively. The inhibition constant for quercetin (**35**) was the lowest, suggesting that the inhibitory effect of this compound is leading among all tested flavonoid structures. This result is consistent with the tyrosinase inhibitory activity test (IC₅₀=44.38\pm0.13 \muM).

3.3. Molecular docking studies

Active compounds were generally predicted to show high affinity to the active site, as represented by their docking scores (Table 3). Compounds **26** and **41** were particularly noteworthy based on their docking scores, which were based on a set of profitable interactions with the enzyme and its cofactors.

Isookanin's (4) binding mode lacked interactions with Cu²⁺ and its ligands (Figure 4(A)), which resulted in a moderate docking score. This result was most likely due to the lack of aromaticity (i.e., a double bond between C2 and C3) of its flavonoid core, which, in the case of other compounds, was able to reach deeper into the copper zone and make π -stacks with the key histidine residues. The lack of aromaticity in isookanin's flavonoid core also cancelled out the compound's planarity and led to bending, which may have made it sterically difficult to approach the copper ions.

Conversely, compounds **17**, **26**, **32**, **35**, and **41** were found to be suitable chelators of Cu^{2+} due to the common flavonoid core and the ionisable OH substituent at the 7th position (Figure 4(B–F)). The ionised hydroxyl was effective even for double Cu^{2+} engagement in the case of **26**, **32** and **41**, which were the best scoring compounds (see Table 3). Aromaticity of the flavonoid core enabled π stacking with the histidine residues serving as



Figure 3. Dixon plots for inhibition of tyrosinase in the presence of compounds: 4 (A), 17 (B), 26 (C), 32 (D), 35 (E), and 41 (F). The concentrations of the compounds were 0.00, 25, and 50 μ M. The substrate L-DOPA concentrations were 0.25, 0.50, 1, and 2 mM.

Table 2. Kinetic analysis of active compounds on tyrosinase.

Table 3. Docking scores of the active flavonoids.

Compound	lype of inhibition	K; (μΜ) ^α	Table of Boelding Secres of the	acare naronolasi
4	non-competitive	18.64 ± 0.53	Compound	Docking score (kcal/mol)
17	non-competitive	11.32 ± 0.77	4	-6.6
26	competitive	40.20 ± 0.46	17	-7.9
32	competitive	9.83 ± 0.57	26	-9.1
35	competitive	8.21 ± 0.86	32	-8.5
41	non-competitive	27.42 ± 0.62	35	-7.9
^a All data are repres	ented as Ki values with standard de	viation from triplicate	41	-10.3

^aAll data are represented as Ki values with standard deviation from triplicate measurements.

copper ligands, as well as His244. The hydroxyl groups on ring B of **17** and **35** formed H bonds with Glu322. The hydroxyphenyl attached to the glucopyranosyl moiety of **32** made additional π stacking with His85. Ring B of **17**, **26**, **35**, and **41** was observed to

face active site entry and disposed to solvent molecules (Figure 5). With three hydroxyls on ring B, **41** was the most advantageous compound in this situation, which contributed to its docking score.



Figure 4. Predicted binding mode of compounds 4 (A), 17 (B), 26 (C), 32 (D), 35 (E), and 41 (F) in the tyrosinase active site. Compounds are represented as colour stick balls, interacting tyrosinase residues as grey sticks, Cu^{2+} as orange spheres, their histidine ligands as wireframes, and binding interactions as colour dashed lines. The distances between Cu^{2+} and interacting atoms are shown in Å.

These results highlight the importance of the flavonoid core with a free hydroxyl at C-7 as a key component for copper chelation and for interactions with the key residues of the tyrosinase active site. The exceptional binding mode of **4** in the catalytic site with respect to its activity can be explained by more effective binding to a possible allosteric site.

3.4. Statistical modelling approach

To create a statistical model, 26 attributes (Table 4) that were consistent with all tested flavonoid compounds and their variables (IC_{50} values) were identified.

Table 5 shows the multivariate linear regression model for the In IC₅₀. Statistical analysis explained more than 50% of the variability of the IC₅₀ variable (adjusted R^2 =50.88%) with p= 0.0002. All 11 independent variables in this approach yield p< 0.2, while five of them (A4, A10, A18, A21 and A22) have a statistically significant influence on the dependent variable (IC₅₀).

Based on these results, the presence of methoxy substitution at C3'(A4) increases the mean IC_{50} value by approximately 4.15 times, and increasing this value (by approximately 2.47 times) relates to methoxy substitution at C7 (A18). Methylation at C8

(A22) caused an increase in the IC₅₀ value, as shown by InIC₅₀ (1.452888), which indicates that, in this case, the mean IC₅₀ increases by approximately 4.28 times. Conversely, the presence of hydroxy substitution at C3 (A10) and hydroxy substitution at C8 (A21) reduced the mean IC₅₀ by approximately 2.83 and 5.11 times, respectively. Overall, statistical modelling suggests that flavonoids with higher antityrosinase activity possess an OH group at C3 and at C8, while methylation of the hydroxyl group at carbon 3 and at carbon 8 notably reduces the inhibitory activity of the molecules.

4. Conclusions

Results from the literature that describe the effect of flavonoids on mushroom tyrosinase activity are dispersed and sometimes contradictory. This dissidence may relate to various experimental conditions (e.g., concentration of enzyme or substrate L-DOPA, wavelength), which led to different ranges of reported inhibitory activity. Furthermore, generally few flavonoids were included in such investigations, which yields restricted structure-activity relationships information. The statistical model developed in this study provides accurate SAR data in a comprehensive format.



Figure 5. Binding interactions of compounds 4 (A), 17 (B), 26 (C), 32 (D), 35 (E), and 41 (F) with the tyrosinase active site residues. Binding interactions are shown as coloured lines, and compound moieties exposed to solvent are highlighted with grey shades.

	Table 4.	Attributes	definitions	used	to	for	the	statistical	anal	vsis
--	----------	------------	-------------	------	----	-----	-----	-------------	------	------

A1

A2

A3

A4

A5

A6

A7

A8

Α9

Definition Number presence or absence of double bond between C2 and C3 OMe substitution at C2' OH substitution at C3' OMe substitution at C3' OH substitution at C4' OMe substitution at C4' OAc substitution at C4' OH substitution at C5' OMe substitution at C6' A10 OH substitution at C3 A11 OMe substitution at C3 A12 O-glc/O-gluc/O-rut/6-deoxy-α-L-man substitution at C3 O-(6"-p-Co)-glc substitution at C3 A13 OH substitution at C5 A14 A15 OMe substitution at C5 glc substitution at C6 A16 OH substitution at C7 A17 OMe substitution at C7 A18 A19 O-rut/O-glc substitution at C7 A20 O-xyl-glc substitution at C7 A21 OH substitution at C8 A22 OMe substitution at C8 A23 glc substitution at C8 A24 3-Me-2-Bu substitution at C8 A25 glc-O-glc/xyl-O-glc substitution at C8 (4"acetoxy-xyl)-O-glc substitution at C8 A26

Table 5 The multivariate linear regression model for the ln IC_{co}

	ine manare	inical regress	ien meaci				
Attribute	Coefficient	e ^{Coefficient}	p Value	[95% Conf. Interval]			
A4	1.423116	4.15003	< 0.001	0.7909708	2.055261		
A5	0.3649103	1.44038	0.126	-0.1077861	0.8376067		
A6	0.4055184	1.50008	0.148	-0.1517169	0.9627536		
A10	-1.041826	0.35281	< 0.001	-1.521979	-0.5616735		
A13	-0.8969235	0.40782	0.088	-1.935625	0.1417784		
A14	-0.4376985	0.64552	0.167	-1.068768	0.1933707		
A15	-1.317022	0.26793	0.063	-2.71015	0.0761047		
A18	0.9049781	2.47188	0.002	0.3562236	1.453733		
A21	-1.630273	0.19588	0.008	-2.805552	-0.4549943		
A22	1.452888	4.27544	0.012	0.3464813	2.559294		
A25	0.5533549	1.73908	0.056	-0.0138585	1.120568		

Adjusted R²=0.5088.

docking scores and statistical data allowed us to identify the characteristics of flavonoid structures that facilitate tyrosinase inhibition: the presence of hydroxyls at C3 and C7, O- and Cglycosylation, methylation and acetylation of OH groups. As in many other cases reported in the literature³⁴, the natural products represent a gold mine for interesting biological activities which can be translated to potential biomedical applications.

Abbreviations: Me: methyl; B: butenyl; Ac: acetyl; glc: glucose; gluc: glucuronide; p-Co: para-coumaroyl; man: mannose; rut: rutinose; xyl: xylose.

Many flavonoids were tested under the same conditions to obtain values that are as close to those in the real world as possible. In summary, a comparison of IC50 values, kinetic reactions, molecular

Acknowledgement

The authors express thanks to J.W. Strawa and A.M. Juszczak from the Medical University of Białystok for isolation of compounds to in vitro studies.

Author contributions

Study design: K.J, and M.T.; Biological evaluation: K.J.; Data Interpretation: K.J.; Computational studies: S.S., and D.S.; Statistical analysis: R.M., and K.J.; Supervised experiments: M.T., and D.S.; Wrote the original paper: K.J., S.S., and R.M.; Manuscript formal analysis: M.T., and C.T.S.

Disclosure statement

No potential conflict of interest was reported by the authors. CT Supuran is Editor-in-Chief of Journal of Enzyme Inhibition and Medicinal Chemistry and he was not involved in the assessment, peer review or decision making process of this paper. The authors have no relevant affiliations of financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Funding

The author(s) reported there is no funding associated with the work featured in this article.

ORCID

Katarzyna Jakimiuk i http://orcid.org/0000-0001-7702-6493 Suat Sari i http://orcid.org/0000-0002-8248-4218 Robert Milewski i http://orcid.org/0000-0001-6241-8283 Claudiu T. Supuran i http://orcid.org/0000-0003-4262-0323 Didem Şöhretoğlu i http://orcid.org/0000-0002-8264-5544 Michał Tomczyk i http://orcid.org/0000-0002-4063-1048

References

- 1. Jakimiuk K, Wink M, Tomczyk M. Flavonoids of the Caryophyllaceae. Phytochem Rev 2021;20:1–40.
- García-Sosa AR, Maran U. Improving the use of ranking in virtual screening against HIV-1 integrase with triangular numbers and including ligand profiling with antitargets. J Chem Inf Model 2014;54:3172–85.
- 3. Glisic S, Sencanski M, Perovic V, et al. Arginase flavonoid anti-leishmanial *in silico* inhibitors flagged against anti-targets. Molecules 2016;21:589–14.
- Flurkey WH, Inlow JK. Proteolytic processing of polyphenol oxidase from plants and fungi. J Inorg Biochem 2008;102: 2160–70.
- Ismaya WT, Rozeboom HJ, Weijn A, et al. Crystal structure of Agaricus bisporus mushroom tyrosinase: identity of the tetramer subunits and interaction with tropolone. Biochem 2011; 50:5477–86.
- 6. Klabunde T, Eicken C, Sacchettini JC, Krebs B. Crystal structure of a plant catechol oxidase containing a dicopper center. Nat Struct Mo. Biol 1998;5:1084–90.
- 7. Zolghadri S, Bahrami A, Hassan Khan MT, et al. A comprehensive review on tyrosinase inhibitors. J Enzyme Inhib Med Chem 2019;34:279–309.
- 8. Hazes B, Magnus K, Bonaventura C, et al. Crystal structure of deoxygenated *Limulus polyphemus* subunit II hemocyanin at

2.18 A resolution: clues for a mechanism for allosteric regulation. Protein Sci 1993;2:597–619.

- 9. Ferro S, Deri B, Germanò MP, et al. Targeting tyrosinase: development and structural insights of novel inhibitors bearing arylpiperidine and arylpiperazine fragments. J Med Chem 2018;61:3908–17.
- Lai X, Wichers HJ, Soler-Lopez M, Dijkstra BW. Structure and function of human tyrosinase and tyrosinase-related proteins. Chem–An Eur J 2018;24:47–55.
- Şöhretoğlu D, Sari S, Barut B, Özel A. Tyrosinase inhibition by some flavonoids: inhibitory activity, mechanism by in vitro and in silico studies. Bioorg Chem 2018;81:168–74.
- 12. Isidorov V, Szoka L, Nazaruk J. Cytotoxicity of white birch bud extracts: perspectives for therapy of tumours. PLoS One 2018;13:e0201949–10.
- Nazaruk J, Jakoniuk P. Flavonoid composition and antimicrobial activity of *Cirsium rivulare* (Jacq.) all flowers. J Ethnopharmacol 2005;102:208–12.
- 14. Tomczyk M, Gudej J. Quercetin and kaempferol glycosides from *Ficaria verna* flowers and their structure studied by 2D NMR spectroscopy. Pol J Chem 2002;76:1601–5.
- Strawa J, Wajs-Bonikowska A, Jakimiuk K, et al. Phytochemical examination of woolly burdock *Arctium* tomentosum leaves and flower heads. Chem Nat Compd 2020;56:345–7.
- 16. Juszczak AM, Czarnomysy R, Strawa JW, et al. *In vitro* anticancer potential of *Jasione montana* and its main components against human amelanotic melanoma cells. Int J Mol Sci 2021;22:1–25.
- 17. Strawa J, Galanty A, Jakimiuk K, Grabowska K, Podolak I, Tomczyk M. Cytotoxic effect on human melanoma cell lines and tyrosinase inhibition of *Hottonia palustris*. Poster session presented at: 69th International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research; 5-9 September 2021; Bonn, Germany; Virtual Conference.
- Jakimiuk K, Strawa JW, Granica S, Tomczyk M. New flavone C-glycosides from *Scleranthus perennis* and their anti-collagenase activity. Molecules 2021;26:5631–10.
- Tomczyk M. Secondary metabolites from *Potentilla recta* L. and *Drymocallis rupestris* (L.) Soják (syn. *Potentilla rupestris* L.) (Rosaceae). Biochem Syst Ecol 2011;39:893–6.
- 20. Gudej J, Tomczyk M. Polyphenolic compounds from flowers of *Ficaria verna* Huds. Acta Pol Pharm 1999;56:475–6.
- Ciganović P, Jakimiuk K, Tomczyk M, Zovko-Končić M. Glycerolic licorice extracts as active cosmeceutical ingredients: extraction optimization, chemical characterization, and biological activity. Antioxidants 2019;8:445–14.
- Yoshino M, Murakami K. A graphical method for determining inhibition constants. J Enzyme Inhib Med Chem 2009;24: 1288–90.
- 23. Butt ARS, Abbasi MA, Rehman AA, et al. Synthesis and structure-activity relationship of tyrosinase inhibiting novel biheterocyclic acetamides: mechanistic insights through enzyme inhibition, kinetics and computational studies. Bioorg Chem 2019;86:459–72.
- 24. Lu C, Wu C, Ghoreishi D, et al. OPLS4: improving force field accuracy on challenging regimes of chemical space. J Chem Theory Comput 2021;17:4291–300.
- 25. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28:3908–17.
- 26. Sastry GM, Adzhigirey M, Day T, et al. Protein and ligand preparation: parameters, protocols, and influence on virtual

screening enrichments. J Comput Aided Mol Des 2013;27: 221–34.

- 27. Friesner RA, Murphy RB, Repasky MP, et al. Extra precision glide: docking and scoring incorporating a model of hydro-phobic enclosure for protein-ligand complexes. J Med Chem 2006;49:6177–96.
- 28. Jacob V, Hagai T, Soliman K. Structure-activity relationships of flavonoids. Curr Org Chem 2011;15:2641–57.
- 29. Cos P, Ying L, Calomme M, et al. Structure-activity relationship and classification of flavonoids as inhibitors of xanthine oxidase and superoxide scavengers. J Nat Prod 1998;61: 71–6.
- 30. Jakimiuk K, Gesek J, Atanasov AG, Tomczyk M. Flavonoids as inhibitors of human neutrophil elastase. J Enzyme Inhib Med Chem 2021;36:1016–28.
- 31. Zhang L, Zhao X, Tao G-J, et al. Investigating the inhibitory activity and mechanism differences between norartocarpetin and luteolin for tyrosinase: a combinatory kinetic study and computational simulation analysis. Food Chem 2017;223: 40–8.
- 32. Fan M, Zhang G, Hu X, et al. Quercetin as a tyrosinase inhibitor: inhibitory activity, conformational change and mechanism. Food Res Int 2017;100:226–33.
- Lu Y, Chen J, Wei D, et al. Tyrosinase inhibitory effect and inhibitory mechanism of tiliroside from raspberry. J Enzyme Inhib Med Chem 2009;24:1154–60.
- 34. Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov 2021;20:200–16.